Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2 study of GSK5458514 in metastatic castration-resistant prostate cancer
2025-521581-10-00Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of GSK5458514 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by GSK. Primary endpoints: Dose-limiting toxicities, Adverse events and serious adverse events and 1 more. Started Jan 2026; status: completed.
02
Drugs
GSK5458514
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2025-521581-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521581-10-00.